Padeliporfin
Tookad is a light-activated drug for men with low-risk prostate cancer in one side of the prostate. It is infused and then switched on with laser fibres placed in the gland, destroying the cancer-bearing tissue as an alternative to watchful waiting.
Overview
Padeliporfin was authorised in the EU in November 2017 as monotherapy for previously untreated, unilateral, low-risk prostate adenocarcinoma (stage T1c or T2a, Gleason 6, PSA 10 ng/mL or below) in men with a life expectancy of at least 10 years, on the PCM301 phase 3 trial in which vascular-targeted photodynamic therapy roughly halved progression and the need for radical therapy compared with active surveillance, at the cost of transient urinary and erectile symptoms. It is the only focal drug-device therapy for prostate cancer with a marketing authorisation; an FDA advisory committee questioned its benefit over surveillance and it is not approved in the US. Trials in intermediate-risk disease and in upper urinary tract urothelial cancer are ongoing. Dysuria, haematuria and erectile dysfunction are the main adverse effects and patients must avoid light exposure for 48 hours.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas: how tumours escape and what closes the route · Lines of therapy.
Approvals
| Region | Year | Indication |
|---|---|---|
| EU | 2017 | Unilateral, low-risk, previously untreated prostate adenocarcinoma in men with life expectancy of at least 10 years (Tookad VTP) |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Padeliporfin" OR ABSTRACT:"Padeliporfin" OR TITLE:"Tookad" OR ABSTRACT:"Tookad" OR TITLE:"WST11" OR ABSTRACT:"WST11" OR TITLE:"Padeliporfin di-potassium" OR ABSTRACT:"Padeliporfin di-potassium" OR TITLE:"Vascular-targeted photodynamic therapy VTP" OR ABSTRACT:"Vascular-targeted photodynamic therapy VTP") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Padeliporfin, not a curated reading list.
Pages like this
not linked directly; found by shared links- CompanyMDxHealth
Shares Active surveillance, Prostate cancer.
- TermGleason score and Grade Group
Shares Active surveillance and observation, Active surveillance, Prostate cancer.
- ProductSamarium-153 lexidronam
Shares Prostate cancer and the tag ema-list.
- TrialProtecT
Shares Active surveillance and observation, Active surveillance, Prostate cancer.
- ProductOncotype DX Genomic Prostate Score
Shares Active surveillance and observation, Active surveillance, Prostate cancer.
- TermMGUS and smouldering myeloma
Shares Active surveillance and observation, Active surveillance.
- TermDuctal carcinoma in situ (DCIS)
Shares Active surveillance and observation, Active surveillance.
- ProductProlaris
Shares Active surveillance and observation, Active surveillance, Prostate cancer.